Chemotherapy of invasive thymoma.

Fornasiero, A.; Daniele, O; Ghiotto, Cristina; Sartori, F; Rea, Federico; Piazza, Mario; Fiore-Donati, L; Morandi, Paolo; Aversa, Savina; Paccagnella, Adriano

doi:10.1200/jco.1990.8.8.1419

Cited by 107 publications

(43 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, thymomas are generally reported to be chemotherapy-sensitive tumours, with response rates of 50 -70% to combination chemotherapy (Fornasiero et al, 1990;Loehrer et al, 1994Loehrer et al, , 1997Loehrer et al, , 2001Giaccone et al, 1996;Berruti et al, 1999;Kim et al, 2004;Lucchi et al, 2006;Yokoi et al, 2007). Active agents include cisplatin (CDDP), vincristine (VCR), doxorubicin (ADM), etoposide (ETP), cyclophosphamide (CPM) and ifosfamide (IFX).…”

mentioning

confidence: 99%

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: To evaluate the safety and efficacy of dose-dense weekly chemotherapy in the treatment of advanced thymoma. METHODS: Subjects comprised patients with histologically documented chemotherapy-naïve thymoma with stage-IVa or IVb disease. Thymic carcinoma, carcinoid or lymphoma cases were excluded. Patients received 9 weeks of chemotherapy: cisplatin (25 mg m À2 ) on weeks 1 -9; vincristine (1 mg m À2 ) on weeks 1, 2, 4, 6 and 8; and doxorubicin (40 mg m À2 ) and etoposide (80 mg m À2 ) on days 1 -3 of weeks 1, 3, 5, 7 and 9. Chemotherapy courses were supported by granulocyte colony-stimulating factor. Post-protocol local therapy was allowed. RESULTS: From July 1997 to March 2004, 30 patients were entered. Three were ineligible due to different histology. Chemotherapyassociated toxicity was mainly haematological and was well tolerated, with no deaths due to toxicity, and 87% of patients completed the planned 9-week regimen. Overall response rate was 59%, with 16 of the 27 eligible patients achieving partial response. Median progression-fee survival (PFS) was 0.79 years (95% confidence interval: 0.52 -1.40 years), and PFS at 1 and 2 years was 37 and 15%, respectively. Overall survival rates at 2 and 5 years were 89 and 65%, respectively. CONCLUSION: In stage-IV thymoma patients, weekly dose-dense chemotherapy offers similar activity to conventional regimens.

show abstract

mentioning

confidence: 99%

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Timik epitelyal tümörler (TET) nadir görülür ve tüm kanserlerin yaklaşık %0,2-1,5'ini oluştururlar (1) . En sık timik tümörler timoma, timik karsinoma ve timik karsinoiddir.…”

Section: Introductionunclassified

Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A single institutional experience

Temelli¹,

Ekici²,

Kekilli³

2017

Okmeydani Medical Journal

View full text Add to dashboard Cite

Amaç: Timik epitelyal tümörler (TET) nadir görülür ve Material and Methods: We retrospectively analysed clinical features of TET and the correlation of World Health Organisation (WHO) histologic classification and Masaoka staging system with radiotherapy modalities in 18 patients from 2004 to 2015.Results: Our patients' male/female ratio was 10/8. Median age was 49 (range: 18-76). Fifteen patients were thymoma and 3 patients were thymic carcinoma. According to Masaoka staging; patients were distributed as Stage I 5.6% (n=1), Stage II 50% (n=9), Stage III 16.7% (n=3) and Stage IV 27,7% (n=5)

show abstract

“…Prolonged disease control is possible, but tumour eradication is not expected. Several studies, both prospective and retrospective, described several regimens for definite chemotherapy (table 5) [90][91][92][93][94][95][96][97][98][99], but because there are no randomised studies it is unclear which are best; multi-agent combination regimens and anthracyclinebased regimens appear to have improved response rates compared to others, especially the etoposide, ifosfamide and cisplatin combinations. In general, a combination regimen is recommended for at least three and no more than six cycles ( fig.…”

Section: Palliative-intent Definite Chemotherapymentioning

confidence: 99%

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Girard¹

2013

European Respiratory Review

View full text Add to dashboard Cite

Thymic epithelial tumours represent a wide range of anatomical, clinical, histological and molecular malignant entities that may be aggressive and difficult to treat. The histopathological classification distinguishes thymomas from thymic carcinomas. Thymomas may be associated with autoimmune disorders.The management of thymic epithelial tumours is a paradigm of co-operation between clinicians, surgeons and pathologists, from establishing the diagnosis to organising the multimodal therapeutic strategy. Surgery is the mainstay of the curative-intent treatment, as complete resection represents the most significantly favourable prognostic factor on overall survival. In case of invasion of intra-thoracic structures and/or dissemination to the pleura and the pericardium, precluding complete resection to be achieved, primary chemotherapy has been used to reduce the tumour burden, possibly allowing subsequent surgery and/or radiotherapy.Novel strategies are needed, especially for refractory, recurrent tumours and thymic carcinomas, which carry a poor prognosis. Personalised approaches are currently being developed, as potentially ''druggable'' molecular targets are emerging from recent integrated genomic analyses. Along with the large variety of questions relative to the treatment strategy, thymic epithelial tumours represent a model of therapeutic implementation and achievement in orphan thoracic oncology, showing how the advent of new results induces new questions, as well as diversifies further clinical research directions and international collaborative initiatives.

show abstract

Chemotherapy of invasive thymoma.

Cited by 107 publications

References 16 publications

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A single institutional experience

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Contact Info

Product

Resources

About